Vaccine to prevent ovarian cancer moves closer to clinical trials
July 01, 2026
Scientists in the UK are developing a pioneering vaccine designed to train the immune system to detect the earliest warning signs of ovarian cancer. If successful, it could mark a significant shift from treating ovarian cancer to preventing it. Our Research Team tuned into a recent webinar to listen to the latest updates about the OvarianVax vaccine development!
Reading time: 3 minutes
Key points
- OvarianVax is a vaccine to prevent ovarian cancer
- It's being developed by a team at the University of Oxford
- The project has secured major funding from Cancer Research UK
- Clinical trials are at least two years away
What if there was a way to prevent ovarian cancer? Scientists in the UK are developing a pioneering vaccine designed to train the immune system to detect the earliest warning signs of the disease and nip it in the bud.
Ovarian cancer is often diagnosed late and is difficult to treat. A vaccine to prevent it would be a major breakthrough for the most lethal gynaecological cancer, which has a five‑year survival rate of just 49 per cent.
OvarianVax is a vaccine in development by a team at the University of Oxford, UK, which has been supported by not-for-profit Ovarian Cancer Action UK and now with major funding from Cancer Research UK.
The potential vaccine is designed to intervene at the earliest stages, well before any symptoms appear. If successful, it could shift the focus from treating ovarian cancer to preventing it altogether, using the body’s own defences to stop the disease before it begins.
This approach is particularly significant for people at high genetic risk, such as BRCA1/2 mutation carriers. For these individuals, the most effective current preventative option is invasive surgery, such as prophylactic salpingo-oophorectomy, involving the removal of the ovaries and fallopian tubes – an intervention that carries its own risks and long-term effects. A vaccine could be a game-changer for people with genetic risk.
How would OvarianVax work?
This vaccine is designed to target serous ovarian cancer, the most common subtype accounting for more than 70 per cent of cases, which typically starts in the fallopian tubes.
Scientists have pinpointed tell‑tale ‘signatures’ that mark the earliest cancer‑like changes in the fallopian tubes, like faint, smokeless sparks that could one day take hold. OvarianVax is designed to equip the immune system - the body’s fire brigade - with a manual to detect those ‘sparks’ as soon as they appear.
The vaccine works by delivering tiny protein fragments, known as epitopes, which represent the early “signatures” of cancer. These epitopes are derived from abnormal, precancerous cells and capture the key features of those early changes.
These fragments cannot cause disease; instead, they safely mimic early warning signals of cancer. This mimicry is central to how vaccines work, allowing the immune system to practise recognising a threat in advance. In doing so, OvarianVax trains immune cells to identify and respond rapidly to the earliest signs of serous ovarian cancer, stopping it before it can take hold.
The science behind OvarianVax
A decade of research has shown many ovarian cancers begin in the fallopian tubes and early changes can evade detection by the immune system. OvarianVax uses two key components to target early ‘sparks’.
The first component is the ‘payload.’ This is the active component – the epitopes - that trains the immune system to recognise and respond to a specific target.
The second component is the vehicle that delivers the payload into the body’s immune cells.
Researchers screened more than 120 epitopes using blood samples from healthy volunteers to select those that trigger the strongest immune responses. The team reports it has successfully combined the most promising ones into a single vaccine.
What's next?
OvarianVax is in the preclinical stage and has not yet been tested in people. Over the next one to two years, researchers aim to finalise the most effective set of epitopes, complete testing in laboratory models, and identify the best delivery system. A key experiment underway will test whether trained immune cells can actually block healthy fallopian tube cells from turning cancerous - and ideally kill those that do. If these steps succeed and the right regulatory approvals and funding follow, first‑in‑human trials could begin within about two years.
What does this mean for people with ovarian cancer?
Initial trials are likely to focus on people at highest risk, including those with BRCA1 or BRCA2 gene mutations. Starting with high‑risk carriers allows smaller trials with faster results, which can then inform broader population use and help streamline the approval process.
Longer‑term studies would assess whether the vaccine ultimately reduces ovarian cancer incidence. Separate trials may also explore whether it could help prevent cancer from returning after treatment.
How far away is the vaccine from use?
OvarianVax is not yet ready for clinical use. But if the research continues to progress as hoped, it represents a significant step toward a future where one of the most challenging cancers could be prevented - beginning with those at greatest risk and potentially expanding from there.
This article was informed by a recent public webinar hosted by Ovarian Cancer Action UK, a leading UK charity dedicated to defeating ovarian cancer through research. This was the first public presentation of the latest laboratory progress on OvarianVax.
- More about OvarianVax: https://ovarian.org.uk/our-research/our-research-projects/ovarian-cancer-vaccine-ovarianvax-and-what-you-need-to-know/
- OvarianVax Webinar hosted by OCA: https://ovarian.org.uk/our-research/ovarianvax/ovarianvax-update-webinar-2026/
- Epitopes are small, specific pieces of a protein (often from abnormal or diseased cells) that the immune system can recognise. In vaccines, epitopes act as signals that help train immune cells to detect and respond to a particular disease.
- Payload refers to active component delivered by a vaccine or therapy. In this context, it refers to the epitopes (or other biological material) carried by the vaccine to stimulate an immune response.
- Precancerous cells are abnormal cells that show early changes which could develop into cancer over time but are not yet cancerous. Detecting and targeting these cells early can help prevent cancer from forming.
- Serous ovarian cancer is the most common form of epithelial ovarian cancer. Serous ovarian cancers most commonly arise from the cells in the fallopian tubes. It is divided into high-grade (aggressive, common) and low-grade (slow-growing) types.
Get the latest news, stories & updates.
